Andrew Bellinger - 17 Jun 2021 Form 4 Insider Report for Verve Therapeutics, Inc. (VERV)

Role
Chief Scientific Officer
Signature
/s/ Andrew Ashe, as Attorney-in-Fact for Andrew Bellinger
Issuer symbol
VERV
Transactions as of
17 Jun 2021
Net transactions value
+$95,000
Form type
4
Filing time
21 Jun 2021, 18:21:04 UTC
Previous filing
16 Jun 2021
Next filing
17 Dec 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VERV Common Stock Purchase $95,000 +5,000 $19.00 5,000 21 Jun 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VERV Stock Option (right to buy) Award $0 +21,599 $0.000000 21,599 17 Jun 2021 Common Stock 21,599 $19.00 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option was granted on June 17, 2021. 25% of the shares underlying the option will vest on June 17, 2022, and the remainder are scheduled to vest in equal monthly installments thereafter until June 17, 2025.